Skip to main content
Top
Published in: Clinical Rheumatology 9/2021

01-09-2021 | Musculoskeletal Pain | Perspectives in Rheumatology

Refractory fibromyalgia

Authors: Luis F. Vidal, Osvaldo Messina, Tamara Rodríguez, Maritza Vidal, Carlos Pineda, Rasec Morales, Antonio Collado

Published in: Clinical Rheumatology | Issue 9/2021

Login to get access

Abstract

In the medical literature, there are only a few references on refractory fibromyalgia and there is no consensus definition available on this concept. Some definitions of refractory fibromyalgia have been proposed based on the lack of response to a number of medications, and perhaps the most appropriate term is treatment-refractory fibromyalgia. To achieve the definition of treatment-refractory fibromyalgia, it is necessary to consider several previous steps, such as making sure the diagnosis has been made properly and a differential diagnosis with entities that can mimic fibromyalgia symptoms (including complete physical examination and laboratory test) has been made. The possibility that another factor that alters the response to treatment should be investigated, and in particular review all prescribed medication and search for some non-medical reasons that could mask the response to treatment (e.g., legal compensation). The definition of refractory fibromyalgia is complex and probably should include a lack of response to a specified number of drugs or to combination therapy with at least two non-pharmacological measures. In this article, it is not our purpose to present a formal definition, but to raise the possible bases for this purpose. We believe that it is a subject that must be discussed extensively before reaching a consensus definition.
Key Points
• There is no appropriate definition to classify fibromyalgia patients who do not respond to the usual pharmacological and non-pharmacological measures according to the national or international guidelines.
• A consensus definition is required to classify these patients, which could help standardize future management strategies. In this article, we propose the bases on which refractory fibromyalgia could be defined.
Literature
1.
go back to reference Häuser W, Fitzcharles MA (2018) Facts and myths pertaining to fibromyalgia. Dialogues Clin Neurosci 20(1):53CrossRef Häuser W, Fitzcharles MA (2018) Facts and myths pertaining to fibromyalgia. Dialogues Clin Neurosci 20(1):53CrossRef
2.
go back to reference Arnold LM, Gebke KB, Choy EHS (2016) Fibromyalgia: management strategies for primary care providers. Int J Clin Pract 70(2):99–112CrossRef Arnold LM, Gebke KB, Choy EHS (2016) Fibromyalgia: management strategies for primary care providers. Int J Clin Pract 70(2):99–112CrossRef
3.
go back to reference Heymann RE, Paiva ES, Martinez JE et al (2017) New guidelines for the diagnosis of fibromyalgia. Rev Bras Reumatol 57:s467-476CrossRef Heymann RE, Paiva ES, Martinez JE et al (2017) New guidelines for the diagnosis of fibromyalgia. Rev Bras Reumatol 57:s467-476CrossRef
4.
go back to reference Ablin JN, Buskila D (2015) Update on the genetics of the fibromyalgia syndrome. Best Pract Res Clin Rheumatol 29(1):20–28CrossRef Ablin JN, Buskila D (2015) Update on the genetics of the fibromyalgia syndrome. Best Pract Res Clin Rheumatol 29(1):20–28CrossRef
5.
go back to reference Bennett R (2016) Shining a light on fibromyalgia treatment. Nat Rev Rheumatol 12(10):568–569CrossRef Bennett R (2016) Shining a light on fibromyalgia treatment. Nat Rev Rheumatol 12(10):568–569CrossRef
6.
go back to reference Copay AG, Subach R, Glassman SD et al (2007) Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 7(5):541–546CrossRef Copay AG, Subach R, Glassman SD et al (2007) Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 7(5):541–546CrossRef
7.
go back to reference Choy EH, Arnold LM, Clauw DJ et al (2009) Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol 36:2330–2334CrossRef Choy EH, Arnold LM, Clauw DJ et al (2009) Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol 36:2330–2334CrossRef
8.
go back to reference Revicki D, Hays RD, Cella D et al (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102–109CrossRef Revicki D, Hays RD, Cella D et al (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102–109CrossRef
9.
go back to reference Bennet RM, Bushmakin AG, Cappelleri JC et al (2009) Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 36:1304–1311CrossRef Bennet RM, Bushmakin AG, Cappelleri JC et al (2009) Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 36:1304–1311CrossRef
10.
go back to reference Geisser ME, Clauw DJ, Strand V et al (2010) Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. Pain 149:373–378CrossRef Geisser ME, Clauw DJ, Strand V et al (2010) Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. Pain 149:373–378CrossRef
11.
go back to reference Arnold LM, Zlateva G, Sadosky A et al (2011) Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. Pain Med 12:260–267CrossRef Arnold LM, Zlateva G, Sadosky A et al (2011) Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. Pain Med 12:260–267CrossRef
12.
go back to reference Hudson JI, Arnold LM, Bradley LA et al (2009) What makes fibromyalgia patients feel better? Correlations between patient global impression of improvement and changes in clinical symptoms and function: a pooled analysis of four, randomized, placebo-controlled trials of duloxetine. J Rheumatol 36:2517–2522CrossRef Hudson JI, Arnold LM, Bradley LA et al (2009) What makes fibromyalgia patients feel better? Correlations between patient global impression of improvement and changes in clinical symptoms and function: a pooled analysis of four, randomized, placebo-controlled trials of duloxetine. J Rheumatol 36:2517–2522CrossRef
13.
go back to reference Arnold LM, Williams DA, Hudson JI et al (2012) Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum 64(3):885–894CrossRef Arnold LM, Williams DA, Hudson JI et al (2012) Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum 64(3):885–894CrossRef
14.
go back to reference Nuesch E, Häuser W, Bernardy K et al (2013) Comparative efficacy of pharmacological and nonpharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 72:955–962CrossRef Nuesch E, Häuser W, Bernardy K et al (2013) Comparative efficacy of pharmacological and nonpharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 72:955–962CrossRef
15.
go back to reference Holman A (1998) Effect of lorazepam on pain score for refractory fibromyalgia. Arthritis Rheum 41(9) Holman A (1998) Effect of lorazepam on pain score for refractory fibromyalgia. Arthritis Rheum 41(9)
16.
go back to reference Dworkin R, Sharma U, Stacey B et al (2005) Long-term treatment of neuropathic pain and fibromyalgia syndrome with pregabalin in treatment-refractory patients. J Pain 6(3):S30CrossRef Dworkin R, Sharma U, Stacey B et al (2005) Long-term treatment of neuropathic pain and fibromyalgia syndrome with pregabalin in treatment-refractory patients. J Pain 6(3):S30CrossRef
17.
go back to reference Stacey BR, Emir B, Petersel D et al (2010) Pregabalin in treatment-refractory fibromyalgia. Open Rheumatol J 4:35CrossRef Stacey BR, Emir B, Petersel D et al (2010) Pregabalin in treatment-refractory fibromyalgia. Open Rheumatol J 4:35CrossRef
18.
go back to reference Fitzcharles MA, Ste-Marie PA, Goldenberg DL et al (2013) Canadian guidelines for the diagnosis and management of Fibromyalgia syndrome: executive summary. Pain Res Manag 18(3):119–126CrossRef Fitzcharles MA, Ste-Marie PA, Goldenberg DL et al (2013) Canadian guidelines for the diagnosis and management of Fibromyalgia syndrome: executive summary. Pain Res Manag 18(3):119–126CrossRef
19.
go back to reference Fitzcharles MA, Shir Y, Ablin JN el at (2013) Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines. Evid Based Complement Alternat Med 2013:485272 Fitzcharles MA, Shir Y, Ablin JN el at (2013) Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines. Evid Based Complement Alternat Med 2013:485272
20.
go back to reference Salaffi F, Gerardi MC, Atzeni F et al (2017) The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis. Rheumatol Int 37(12):2035–2042CrossRef Salaffi F, Gerardi MC, Atzeni F et al (2017) The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis. Rheumatol Int 37(12):2035–2042CrossRef
21.
go back to reference Fitzcharles MA, Perrot S, Häuser W (2018) Comorbid fibromyalgia: a qualitative review of prevalence and importance. Eur J Pain 22(9):1565–1576CrossRef Fitzcharles MA, Perrot S, Häuser W (2018) Comorbid fibromyalgia: a qualitative review of prevalence and importance. Eur J Pain 22(9):1565–1576CrossRef
22.
go back to reference Häuser W, Perrot S, Sommer C et al (2017) Diagnostic confounders of chronic widespread pain: not always fibromyalgia. Pain Rep 2(3) Häuser W, Perrot S, Sommer C et al (2017) Diagnostic confounders of chronic widespread pain: not always fibromyalgia. Pain Rep 2(3)
23.
go back to reference López-Medina C, Moltó A (2020) Comorbid pain in axial spondyloarthritis, including fibromyalgia. Ther Adv Musculoskelet Dis 12:1759720X20966123CrossRef López-Medina C, Moltó A (2020) Comorbid pain in axial spondyloarthritis, including fibromyalgia. Ther Adv Musculoskelet Dis 12:1759720X20966123CrossRef
24.
go back to reference Arendt-Nielsen L, Nie H, Laursen MB et al (2010) Sensitization in patients with painful knee osteoarthritis. Pain 149(3):573–581CrossRef Arendt-Nielsen L, Nie H, Laursen MB et al (2010) Sensitization in patients with painful knee osteoarthritis. Pain 149(3):573–581CrossRef
25.
go back to reference Fingleton C, Smart K, Moloney N et al (2015) Pain sensitization in people with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthr Cartil 23:1043–1056CrossRef Fingleton C, Smart K, Moloney N et al (2015) Pain sensitization in people with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthr Cartil 23:1043–1056CrossRef
26.
go back to reference Bazzichi L, Rossi A, Giuliano T et al (2007) Association between thyroid autoimmunity and fibromyalgic disease severity. Clin Rheumatol 26(12):2115–2120CrossRef Bazzichi L, Rossi A, Giuliano T et al (2007) Association between thyroid autoimmunity and fibromyalgic disease severity. Clin Rheumatol 26(12):2115–2120CrossRef
27.
go back to reference Haliloglu S, Ekinci B, Uzkeser H et al (2017) Fibromyalgia in patients with thyroid autoimmunity: prevalence and relationship with disease activity. Clin Rheumatol 36(7):1617–1621CrossRef Haliloglu S, Ekinci B, Uzkeser H et al (2017) Fibromyalgia in patients with thyroid autoimmunity: prevalence and relationship with disease activity. Clin Rheumatol 36(7):1617–1621CrossRef
28.
go back to reference Tagoe CE, Sheth T, Golub E et al (2019) Rheumatic associations of autoimmune thyroid disease: a systematic review. Clin Rheumatol 38(7):1801–1809CrossRef Tagoe CE, Sheth T, Golub E et al (2019) Rheumatic associations of autoimmune thyroid disease: a systematic review. Clin Rheumatol 38(7):1801–1809CrossRef
30.
go back to reference Vidal LF, Morales R, Cueva C et al (2019) Serum levels of vitamin D in women treated at rheumatology services in Lima. Int J Clin Rheumatol 14(3):105–112 Vidal LF, Morales R, Cueva C et al (2019) Serum levels of vitamin D in women treated at rheumatology services in Lima. Int J Clin Rheumatol 14(3):105–112
31.
go back to reference Häuser W, Perrot S, Clauw DJ et al (2018) Unravelling fibromyalgia—steps toward individualized management. J Pain 19(2):125–134CrossRef Häuser W, Perrot S, Clauw DJ et al (2018) Unravelling fibromyalgia—steps toward individualized management. J Pain 19(2):125–134CrossRef
32.
go back to reference Affaitati G, Costantini R, Fabrizio A et al (2011) Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain 15(1):61–69CrossRef Affaitati G, Costantini R, Fabrizio A et al (2011) Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain 15(1):61–69CrossRef
33.
go back to reference Häuser W, Ablin J, Perrot S et al (2017) Management of fibromyalgia: practical guides from recent evidence-based guidelines. Pol Arch Intern Med 127(1):47–56CrossRef Häuser W, Ablin J, Perrot S et al (2017) Management of fibromyalgia: practical guides from recent evidence-based guidelines. Pol Arch Intern Med 127(1):47–56CrossRef
34.
go back to reference Smith JD, Terpening CM, Schmidt SO et al (2001) Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins. Ann Pharmacother 35(6):702–706CrossRef Smith JD, Terpening CM, Schmidt SO et al (2001) Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins. Ann Pharmacother 35(6):702–706CrossRef
35.
go back to reference Dodd S, Horgan D, Malhi GS et al (2005) To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 89(1–3):1–11CrossRef Dodd S, Horgan D, Malhi GS et al (2005) To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 89(1–3):1–11CrossRef
36.
go back to reference Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53(8):649–659CrossRef Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53(8):649–659CrossRef
37.
go back to reference Souery D, Papakostas GI, Trivedi MH (2006) Treatment-resistant depression. J Clin Psychiatry 67(16) Souery D, Papakostas GI, Trivedi MH (2006) Treatment-resistant depression. J Clin Psychiatry 67(16)
Metadata
Title
Refractory fibromyalgia
Authors
Luis F. Vidal
Osvaldo Messina
Tamara Rodríguez
Maritza Vidal
Carlos Pineda
Rasec Morales
Antonio Collado
Publication date
01-09-2021
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 9/2021
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-021-05818-0

Other articles of this Issue 9/2021

Clinical Rheumatology 9/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.